An observational study published in BMJ Medicine analyzed electronic health records of 333,687 U.S. veterans with type 2 diabetes and found that continuous use of GLP-1 receptor agonists was associated with significantly lower rates of major cardiovascular events compared with sulfonylureas. The analysis included 132,551 individuals prescribed GLP-1 medications and 201,136 prescribed sulfonylureas, with outcomes tracked over three years. This was not a randomized controlled trial; it was a retrospective observational cohort study, which limits causal inference due to potential confounding factors. No conflicts of interest were reported in the Healthline coverage of the research. Participants who maintained uninterrupted GLP-1 therapy showed an 18% reduction in major cardiovascular events relative to the sulfonylurea group. Those who used GLP-1 drugs for two or 2.5 years before stopping experienced 7% and 15% risk reductions, respectively, while those who discontinued after 18 months or less showed no significant benefit. Interruptions of just six months were associated with a 4-8% increase in cardiovascular risk compared with continuous users. Discontinuing for one to two years without resuming was linked to a 14-22% higher risk. Senior author Ziyad Al-Aly, MD, emphasized that insufficient attention is paid to the consequences of stopping these medications. Expert Robert Glatter, MD, not involved in the study, noted that GLP-1 drugs appear to reduce cardiovascular risk through multiple pathways including glycemic control, blood pressure reduction, anti-inflammatory effects, and possible direct vascular protection, independent of weight loss alone. The source article is available at https://www.healthline.com/health-news/stopping-glp-1-drugs-reverse-cardiovascular-benefits. Clinicians recommend consulting healthcare providers before stopping GLP-1 therapy and stress the importance of sustained lifestyle measures.